2. Search Result
Search Result
Results for "

ATP+Citrate+Lyase

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

3

Natural
Products

2

Recombinant Proteins

2

Isotope-Labeled Compounds

6

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16450
    SB 204990
    Maximum Cited Publications
    25 Publications Verification

    		 ATP Citrate Lyase Metabolic Disease
    SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.
    SB 204990
  • HY-12357
    Bempedoic acid
    20+ Cited Publications

    ETC-1002; ESP-55016

    		 ATP Citrate Lyase AMPK Metabolic Disease
    Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor . Bempedoic acid (ETC-1002) activates AMPK .
    Bempedoic acid
  • HY-16107
    BMS-303141
    20+ Cited Publications

    		 ATP Citrate Lyase Metabolic Disease
    BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
    BMS-303141
  • HY-127111
    NDI-091143
    2 Publications Verification

    		 ATP Citrate Lyase Cancer
    NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate .
    NDI-091143
  • HY-175606
    EVT0185

    		ATP Citrate Lyase Cancer
    EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .
    EVT0185
  • HY-P1123
    MEDICA16

    		ATP Citrate Lyase Free Fatty Acid Receptor Acetyl-CoA Carboxylase Metabolic Disease
    MEDICA16 is an orally active acetyl-CoA carboxylase and ATP-citrate lyase inhibitor. MEDICA16 limits the acetyl-CoA supply for acetyl-CoA carboxylase, inhibits acetyl-CoA carboxylase activity, exerts citrate-competitive inhibitory effects on ATP-citrate lyase, and reduces hepatic AMPK activity. MEDICA16 can be used in research related to insulin resistance, hyperlipidemia, and obesity .
    MEDICA16
  • HY-N7347
    (-)-Hydroxycitric acid lactone

    Garcinia lactone

    		 ATP Citrate Lyase Metabolic Disease
    (-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .
    (-)-Hydroxycitric acid lactone
  • HY-17640
    Nicodicosapent

    		Fatty Acid Synthase (FASN) Autophagy Metabolic Disease
    Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.
    Nicodicosapent
  • HY-12357S2
    Bempedoic acid-d4

    ETC-1002-d4; ESP-55016-d4

    		 ATP Citrate Lyase AMPK Others
    Bempedoic acid-d4 is the deuterium labeled Bempedoic acid. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK .
    Bempedoic acid-d4
  • HY-177136
    ACLY-IN-2

    		ATP Citrate Lyase Metabolic Disease Inflammation/Immunology Cancer
    ACLY-IN-2 (Compound 7) has inhibitory effect against human ATP citrate lyase (hACLY), with an IC50 of less than 1 nM. ACLY-IN-2 can be studied in research on liver-related diseases, type-2 diabetes, autoimmunity, and cancer .
    ACLY-IN-2
  • HY-12357S
    Bempedoic acid-d5

    ETC-1002-d5; ESP-55016-d5

    		 ATP Citrate Lyase AMPK Metabolic Disease
    Bempedoic acid-d5 is the deuterium labeled Bempedoic acid . Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor . Bempedoic acid (ETC-1002) activates AMPK .
    Bempedoic acid-d5
  • HY-12357R
    Bempedoic acid (Standard)

    ETC-1002 (Standard); ESP-55016 (Standard)

    		 ATP Citrate Lyase AMPK Reference Standards Metabolic Disease
    Bempedoic acid (Standard) is the analytical standard of Bempedoic acid. This product is intended for research and analytical applications. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor . Bempedoic acid (ETC-1002) activates AMPK .
    Bempedoic acid (Standard)
  • HY-N12336
    Gnetuhainin I

    		Others Metabolic Disease
    Gnetuhainin I (Compound 5) is a lignin derived from Pouzolzia zeylanica. Gnetuhainin I shows good inhibitory effect on ATP citrate lyase (ACLY) (IC50=2.63 μM) .
    Gnetuhainin I
  • HY-N7347R
    (-)-Hydroxycitric acid lactone (Standard)

    Garcinia lactone (Standard)

    		 Reference Standards ATP Citrate Lyase Metabolic Disease
    (-)-Hydroxycitric acid lactone (Standard) is the analytical standard of (-)-Hydroxycitric acid lactone. This product is intended for research and analytical applications. (-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .
    (-)-Hydroxycitric acid lactone (Standard)
  • HY-182750
    ACLY-IN-3

    		ATP Citrate Lyase Inflammation/Immunology
    ACLY-IN-3 is an ATP-citrate lyase (ACLY) inhibitor with an IC50 of 0.036 μM and a target Kd of 0.54 μM. ACLY-IN-3 interacts with the allosteric binding site of ACLY to inhibit its activity. ACLY-IN-3 exhibits excellent lipid-lowering effects and alleviates hepatic inflammation and liver fibrosis. ACLY-IN-3 can be used for the research of metabolic dysfunction-associated steatohepatitis .
    ACLY-IN-3
  • HY-182751
    ACLY-IN-4

    		ATP Citrate Lyase Inflammation/Immunology
    ACLY-IN-4 is an ATP-citrate lyase (ACLY) inhibitor with an IC50 of 0.022 μM and a Kd of 0.19 μM. ACLY-IN-4 binds to the allosteric binding site of ACLY. ACLY-IN-4 exhibits hypolipidemic, anti-steatotic, insulin sensitivity-improving, anti-oxidative stress, anti-inflammatory and anti-fibrotic activities. ACLY-IN-4 alleviates hepatic steatosis, systemic insulin resistance, oxidative stress, hepatic inflammation and fibrosis. ACLY-IN-4 can be used for the research of metabolic dysfunction-associated steatohepatitis .
    ACLY-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: